Cambridge Epigenetix

Cambridge Epigenetix appoints Professor Mark Dawson as Scientific Advisor

Monday, November 27, 2017

Cambridge Epigenetix, a pioneer in the development and application of epigenetic technologies, announced the appointment of epigenetics-based therapeutics specialist Professor Mark Dawson to its Scientific Advisory Board (SAB). Professor Dawson brings a wealth of experience in the translation of cancer epigenetics research to clinical practice. The appointment further strengthens CEGX’s panel of opinion leaders providing expert advice across the Company’s key focus areas of epigenetics, oncology, liquid biopsy, diagnostic and therapeutic development.

[Read More]

Cambridge Epigenetix, NuGEN Technologies partner in epigenetics research

Tuesday, August 15, 2017

Cambridge Epigenetix (CEGX) and NuGEN Technologies, leaders in innovative epigenetic technologies, have entered into a partnership agreement to integrate the CEGX TrueMethyl technology for oxidative bisulfite sequencing (oxBS-Seq) with NuGEN’s innovative NGS library preparation kits. The signing of the agreement will enable CEGX to focus on its epigenetic biomarker discovery programmes, both in-house and in partnership with leading biopharma companies, and will further strengthen NuGEN’s epigenetics portfolio of whole genome Methyl-Seq, Reduced Representation Bisulfite Sequencing (RRBS), and patented SPET target enrichment systems.

[Read More]

Cambridge Epigenetix licenses DNA Methylation IP from Boston Children’s Hospital

Tuesday, May 2, 2017

Cambridge Epigenetix, a pioneer in the development and application of epigenetic technologies, has entered into an exclusive license agreement with Boston Children’s Hospital giving access to DNA profiling technologies, which may hold the key to improved diagnoses and treatment of many diseases, including cancer. The licensed intellectual property (IP) is based upon the early findings of Professor Anjana Rao; an expert in immunology and cancer epigenetics, formerly of Boston Children’s Hospital and now with the La Jolla Institute, and a member of the Cambridge Epigenetix Scientific Advisory Board (SAB). Professor Rao’s pioneering research group was the first to identify 5-hydroxymethylcytosine (5hmC) as an important biomarker for cancer diagnosis that cannot be measured by traditional epigenetic sequencing methodologies. She also determined that the ten-eleven translocation (TET) family of enzymes generate 5hmC from 5-methylcytosine (5mC) and are key regulators of cellular differentiation that are frequently mutated in cancer.

[Read More]

Cambridge Epigenetix Establishes Scientific Advisory Board

Monday, March 6, 2017

Cambridge Epigenetix, a developer of epigenetic technologies, has announced the formation of its Scientific Advisory Board (SAB). The SAB comprises experts for Cambridge Epigenetix’s key focus areas, including oncology, liquid biopsy and ageing. They form a key strategic resource and provide their unique research perspectives as the company transitions towards becoming an integrated commercial epigenetic biomarker discovery venture.

[Read More]